Scarica l'app Stockscreener
26.85
3.69%
-1.03
Pre-mercato:
26.84
-0.01
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$27.88
Aprire:
$27.73
Volume 24 ore:
2.00M
Relative Volume:
2.40
Capitalizzazione di mercato:
$2.51B
Reddito:
$4.72M
Utile/perdita netta:
$-277.91M
Rapporto P/E:
-7.1984
EPS:
-3.73
Flusso di cassa netto:
$-203.56M
1 W Prestazione:
-3.56%
1M Prestazione:
-8.58%
6M Prestazione:
-27.39%
1 anno Prestazione:
-47.08%
Intervallo 1D:
$25.83
$28.09
Intervallo di 1 settimana:
$25.83
$29.93
Portata 52W:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
6055 LUSK BLVD., SAN DIEGO, CA
Confronta CRNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
26.85 | 2.67B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Iniziato | Goldman | Neutral |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Crinetics Pharmaceuticals Inc's Q2 2025 Earnings Call Highlights: Strategic Advancements, Financial Resilience Amid Rising Costs. - AInvest
Crinetics Pharmaceuticals' Q2 2025 Earnings: Financial Vulnerability and Clinical Dependencies Amid Pipeline Advancements - AInvest
Investors Might Be Losing Patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) Increasing Losses, as Stock Sheds 3.6% Over the Past Week - 富途牛牛
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Crinetics Pharmaceuticals: A Pipeline-Driven Inflection Point in Endocrine Therapeutics - AInvest
Crinetics 2025 Q2 Earnings Widening Losses Despite Revenue Surge - AInvest
How to read the order book for Crinetics Pharmaceuticals Inc.Free AI Trading Suggestions With Accuracy Focus - Newser
Transcript : Crinetics Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Stifel lowers Crinetics stock price target to $58 from $60, keeps Buy rating - Investing.com Canada
Earnings call transcript: Crinetics Pharmaceuticals Q2 2025 results miss EPS forecast - Investing.com
Crinetics Pharmaceuticals Inc. (CRNX) Shares Soar 11.91% on 150% Revenue Surge - AInvest
Crinetics Pharmaceuticals Q2 Earnings: Revenue Rises, Shares Up - AInvest
Crinetics Pharmaceuticals Q2 Loss Widens, Revenue Rises; Shares up Pre-Bell - MarketScreener
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Crinetics Pharmaceuticals Inc (CRNX) Q2 2025 Earnings Call Highlights: Strategic Advancements ... By GuruFocus - Investing.com Canada
Crinetics Pharmaceuticals Inc (CRNX) Q2 2025 Earnings Call Highl - GuruFocus
Will breakout in Crinetics Pharmaceuticals Inc. lead to full recoveryRisk Adjusted Trade Signal Screening Tool - Newser
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch - TipRanks
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crinetics reports Q2 EPS ($1.23), consensus ($1.10) - TipRanks
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Risk Entry Zone Technical Analysis - Newser
Crinetics Pharma earnings missed by $0.13, revenue topped estimates - Investing.com Canada
Crinetics Q2: $1.2B cash, PDUFA date for PALSONIFY, atumelnant progress. - AInvest
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Crinetics Earnings: $1.2B War Chest Powers PALSONIFY Launch, FDA Decision Looms in September - Stock Titan
Crinetics Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Crinetics CRNX Q2 2025 Earnings Preview Downside Expected on Analyst EPS Downgrades - AInvest
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data - MSN
What are the technical indicators suggesting about Crinetics Pharmaceuticals Inc.Dynamic investment growth - Jammu Links News
Is it the right time to buy Crinetics Pharmaceuticals Inc. stockFastest-growing stock picks - Jammu Links News
What are analysts’ price targets for Crinetics Pharmaceuticals Inc. in the next 12 monthsStay informed with daily expert analysis - Jammu Links News
What institutional investors are buying Crinetics Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
What is the risk reward ratio of investing in Crinetics Pharmaceuticals Inc. stockOver 200% growth - Jammu Links News
How strong is Crinetics Pharmaceuticals Inc. company’s balance sheetGet timely market insights for better trades - Jammu Links News
Real time alert setup for Crinetics Pharmaceuticals Inc. performanceConsistent Gain Plan with AI Support - Newser
When is Crinetics Pharmaceuticals Inc. stock expected to show significant growthInvest smarter with daily trading signals - Jammu Links News
Does Crinetics Pharmaceuticals Inc. stock perform well during market downturnsGet daily updates on market movers and shakers - Jammu Links News
Fibonacci Support Holding Strong in Crinetics Pharmaceuticals Inc.Trade Timing Strategy With Technical Data Explained - metal.it
Are Bears Losing Grip on Crinetics Pharmaceuticals Inc.Real Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline - Yahoo Finance
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyCapital Preserving Trade Plan Templates Shared - metal.it
Can Crinetics Pharmaceuticals Inc. Bounce Back From Weekly LowSmart Investment Tips Gaining Popularity Among Analysts - metal.it
Analyzing net buyer seller activity in Crinetics Pharmaceuticals Inc.Steady Return Plan Based on Data Analysis - Newser
Using data filters to optimize entry into Crinetics Pharmaceuticals Inc.Technical Screener for High Growth Stocks - Newser
Pattern recognition hints at Crinetics Pharmaceuticals Inc. upsideConsistent Return Setup with Exit Strategy - Newser
How does Crinetics Pharmaceuticals Inc. compare to its industry peersInvest confidently with proven investment plans - Jammu Links News
Should I hold or sell Crinetics Pharmaceuticals Inc. stock in 2025Best Dividend Updates For Beginners - jammulinksnews.com
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
3.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):